Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;115(6):863-872.
doi: 10.1007/s00223-024-01236-x. Epub 2024 Jun 5.

Osteogenesis Imperfecta: Skeletal and Non-skeletal Challenges in Adulthood

Affiliations
Review

Osteogenesis Imperfecta: Skeletal and Non-skeletal Challenges in Adulthood

Jannie Dahl Hald et al. Calcif Tissue Int. 2024 Dec.

Abstract

Osteogenesis imperfecta (OI) is a Mendelian connective tissue disorder associated with increased bone fragility and other clinical manifestations most commonly due to abnormalities in production, structure, or post-translational modification of type I collagen. Until recently, most research in OI has focused on the pediatric population and much less attention has been directed at the effects of OI in the adult population. This is a narrative review of the literature focusing on the skeletal as well as non-skeletal manifestations in adults with OI that may affect the aging individual. We found evidence to suggest that OI is a systemic disease which involves not only the skeleton, but also the cardiopulmonary and gastrointestinal system, soft tissues, tendons, muscle, and joints, hearing, eyesight, dental health, and women's health in OI and potentially adds negative affect to health-related quality of life. We aim to guide clinicians as well as draw attention to obvious knowledge gaps and the need for further research in adult OI.

Keywords: Adulthood; Aging; Fractures; Non-skeletal issues; Osteogenesis imperfecta.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: JDH: Investigator, TOPaZ. BL: Investigator, TOPaZ; Advisor and speaker for UCB, Amgen, Gedeon-Richter, speaker for Astra-Zenica and Astellas. LF: None. LLW: none. RJ: None. SSN: None. CR: None. SR: TOPaZ, chief investigator. OS: None. LT: None. EO: Consultancy Amgen, Angitia, Ultragenyx, Sanofi.

Similar articles

Cited by

References

    1. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014. Jun;164A(6):1470–81. doi: 10.1002/ajmg.a.36545. Epub 2014 Apr 8. - DOI - PMC - PubMed
    1. Folkestad L, Hald JD, Tosi L, Raggio C, Semler O, Langdahl B, Ralston SH. Osteogenesis Imperfecta Is More Than a Pediatric Disorder-There Is a Need for Adult Care Evidence to Guide Clinicians. J Clin Endocrinol Metab. 2024. Jan 18;109(2):e866–e867. doi: 10.1210/clinem/dgad423. - DOI - PubMed
    1. Dziechciaż M, Filip R. Biological psychological and social determinants of old age: bio-psycho-social aspects of human aging. Ann Agric Environ Med. 2014;21(4):835–8. doi: 10.5604/12321966.1129943. - DOI - PubMed
    1. Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019. Jul;571(7764):183–192. doi: 10.1038/s41586-019-1365-2. Epub 2019 Jul 10. - DOI - PMC - PubMed
    1. Khosla S, Farr JN, Kirkland JL. Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis. J Clin Endocrinol Metab. 2018. Apr 1;103(4):1282–1290. doi: 10.1210/jc.2017-02694. - DOI - PMC - PubMed

LinkOut - more resources